Armour Thyroid History & Development: From Porcine Extract to Modern NDT

The Earliest Thyroid Therapies: 1878 to 1900

The story of Armour Thyroid begins before the gland's function was fully understood. In 1878, Sir William Gull published the first systematic clinical description of myxedema in adult women, recognizing the syndrome without yet connecting it to thyroid failure [1]. The link between thyroid atrophy and myxedema was established by the Clinical Society of London's 1888 committee report, which reviewed 109 cases and concluded that destruction of the thyroid gland produced the full myxedema picture [2].

George Murray's 1891 Injection Experiment

George Redmayne Murray, a physician in Newcastle, England, made the decisive leap. On June 10, 1891, he injected subcutaneous sheep thyroid extract into a 46-year-old woman with severe myxedema. Within weeks, her facial puffiness receded and her cognition improved [3]. Murray published his results in the British Medical Journal in 1891, describing both the preparation method and the clinical response in detail [3]. This marked the world's first successful organotherapy for an endocrine deficiency.

The Oral Route Is Confirmed

Within a year, Edward Fox and H. Mackenzie independently demonstrated that oral administration of raw sheep thyroid gland produced the same benefit as injection, eliminating the need for sterile preparation [4]. By 1895, oral desiccated thyroid had become the standard of care across Europe and North America, used decades before the thyroid hormones themselves were chemically isolated.

How Armour & Company Entered the Picture

The transition from physician-prepared extracts to a commercial pharmaceutical product occurred in the late 1890s. Armour & Company, the Chicago meatpacking firm founded by Philip Danforth Armour in 1867, had access to enormous quantities of porcine and bovine byproducts [5]. The company began standardizing and tableting desiccated thyroid extract for the pharmaceutical market around 1900, applying the same industrial-scale processing it used for other animal-derived products.

USP Standardization and the Iodine Method

Early preparations varied enormously in potency because thyroid hormone content was not directly measurable. The United States Pharmacopeia addressed this by establishing iodine content as the surrogate for biological activity. Each grain (65 mg) of USP desiccated thyroid was required to contain not less than 0.17% and not more than 0.23% iodine by weight [6]. This standard remains in effect today for all NDT products sold in the United States, including Armour Thyroid.

The USP method provides batch-to-batch consistency for total organic iodine, but it does not specify the precise T4-to-T3 ratio. Porcine thyroid naturally yields an approximately 4:1 T4:T3 ratio, compared to the roughly 20:1 ratio seen in human thyroid secretion [7]. That difference in T3 content is the pharmacokinetic feature that distinguishes NDT from levothyroxine monotherapy and drives much of the modern clinical debate.

Isolating the Active Hormones: 1914 to 1927

Kendall's Thyroxine Isolation

Edward Calvin Kendall at the Mayo Clinic isolated the first active compound from thyroid glands in December 1914, naming it thyroxine [8]. He published the full account in JAMA in 1915. Kendall's work demonstrated that the biological activity of desiccated thyroid resided in a single iodinated compound, not in an ill-defined mixture of glandular proteins [8]. The chemical structure was later confirmed as 3,5,3',5'-tetraiodothyronine (T4) by Charles Harington and George Barger in 1926 [9].

Liothyronine (T3) Comes Later

Triiodothyronine (T3) was not identified as a distinct, more potent hormone until 1952, when Gross and Pitt-Rivers isolated it from thyroid gland and plasma [10]. The finding reframed NDT: the product had always contained both T4 and T3, but practitioners had not known it. The discovery also opened the door to synthetic liothyronine, which reached the market in the late 1950s.

Synthetic Levothyroxine and the Displacement of NDT: 1960 to 1990

Synthetic levothyroxine sodium became commercially available in the United States in 1955 under the brand name Synthroid. The pharmaceutical argument was straightforward: a chemically pure, single-molecule product with a defined dose and stable shelf life should be preferable to an extract whose composition depended on the season, the animal's diet, and the manufacturing run.

Why Prescribers Switched

Three forces accelerated the switch away from NDT during the 1960s and 1970s. First, early radioimmunoassay TSH testing became available, giving clinicians a laboratory target that synthetic T4 could hit predictably. Second, concerns about the variable T3 content of NDT arose after case reports linked high-dose NDT use to transient post-dose T3 surges and palpitations [11]. Third, professional society guidelines, including early American Thyroid Association position statements, began recommending levothyroxine as the drug of choice for primary hypothyroidism [12].

FDA Regulatory Status

Armour Thyroid was never formally submitted through a new drug application (NDA) process. Like many drugs in use before the 1938 Federal Food, Drug, and Cosmetic Act, it retained market authorization under the pre-1938 grandfather clause [13]. This status means the FDA has not required the same efficacy and safety dossier it demands for post-1962 drugs. The FDA does, however, apply current Good Manufacturing Practice (cGMP) standards to NDT production and has issued warning letters to manufacturers for potency deviations in other NDT products, though not specifically for Armour Thyroid in the primary recalls of the 2000s [13].

Mechanism of Action: How Armour Thyroid Works

T4 as a Prohormone

Levothyroxine (T4) circulates largely bound to thyroxine-binding globulin (TBG), albumin, and transthyretin. Peripheral deiodinase enzymes (primarily type 1 and type 2 deiodinase) convert T4 to the active form T3 in target tissues [14]. Because this conversion step varies between individuals based on DIO1 and DIO2 gene polymorphisms, some patients on levothyroxine monotherapy maintain normal TSH but report persistent fatigue and cognitive symptoms, a pattern documented in multiple quality-of-life studies [15].

T3 as the Active Ligand

Triiodothyronine binds thyroid hormone receptors (TRα and TRβ) with roughly 10 to 15 times the affinity of T4 [16]. Nuclear receptor binding drives transcription of genes controlling metabolic rate, cardiac inotropy, thermogenesis, and neuronal development. The T3 in Armour Thyroid is absorbed rapidly from the gut, reaching peak serum concentration within 2 to 4 hours of ingestion, compared to the slower T4 absorption peak at 2 to 4 hours with a longer half-life of approximately 7 days [17].

The Pharmacokinetic Implication of Porcine T3

Each grain (65 mg) of Armour Thyroid contains approximately 38 mcg of T4 and 9 mcg of T3. The T3 fraction produces a transient post-dose serum T3 elevation that resolves within 8 to 10 hours [18]. This peak-and-trough pattern has raised theoretical cardiovascular concerns, particularly in patients with pre-existing arrhythmias. Clinically, dividing the daily dose into twice-daily administration attenuates the T3 peak without altering total daily hormone delivery [19].

Key Clinical Evidence: NDT vs. Levothyroxine

Hoang et al. 2013 (J Clin Endocrinol Metab)

The most-cited head-to-head comparison is Hoang et al. (2013), a single-center, double-blind, crossover trial (N=70) published in the Journal of Clinical Endocrinology and Metabolism [20]. Participants with primary hypothyroidism spent 16 weeks on desiccated thyroid extract and 16 weeks on levothyroxine, with doses titrated to equivalent TSH targets. The study found no statistically significant difference in TSH, free T4, or lipid panels between the two treatments. However, 49% of participants preferred NDT over levothyroxine, while 19% preferred levothyroxine (P<0.001 for preference difference), and participants on NDT lost a mean of 0.9 kg more body weight than on levothyroxine [20]. The authors concluded that NDT "did not result in worse outcomes and may be an acceptable alternative for long-term management."

Idrees et al. And Quality-of-Life Data

A 2019 prospective study by Idrees et al. Examined symptom burden and quality of life in hypothyroid patients on levothyroxine with normal TSH. Approximately 5 to 10% of patients on optimally dosed levothyroxine continue to report symptoms despite biochemical euthyroidism [21]. This residual symptom burden is the clinical niche that NDT advocates cite, arguing that the exogenous T3 in Armour Thyroid compensates for impaired peripheral T4-to-T3 conversion in susceptible individuals [22].

Peterson et al. 2018: Real-World Prescribing Trends

A 2018 survey-based analysis found that NDT use had been rising modestly among endocrinologists and primary care providers in the United States, driven largely by patients seeking alternatives after persistent symptoms on levothyroxine [23]. The same analysis noted that the 2012 American Thyroid Association survey of its membership showed 34% of endocrinologists had prescribed NDT at least once in the prior year [23].

Armour Thyroid Formulation and Manufacturing Today

AbbVie (which acquired Allergan and the Forest Laboratories portfolio through a series of mergers) currently manufactures Armour Thyroid in tablet strengths of 15 mg, 30 mg, 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, and 300 mg, corresponding to 0.25, 0.5, 1, 1.5, 2, 3, 4, and 5 grains respectively [24]. The tablets are made from desiccated porcine thyroid glands and contain calcium stearate, dextrose, microcrystalline cellulose, sodium starch glycolate, and opadry white as inactive excipients [24].

Supply Chain and Shortage History

Armour Thyroid experienced significant availability disruptions in 2009 and 2010 when the product was temporarily back-ordered across large portions of the United States [25]. The shortage prompted the FDA to issue guidance allowing temporary dispensing of alternative NDT products and drove some patients to compound pharmacies. AbbVie has since restructured its manufacturing contracts to reduce single-source porcine material dependency, though the product remains vulnerable to supply chain events affecting the pork processing industry [25].

Allergenicity Considerations

Patients with porcine allergies should not use Armour Thyroid. The product also contains trace amounts of porcine calcitonin, which contributes no known clinical effect at the doses used for thyroid replacement but is occasionally cited in academic discussions of NDT's full hormonal profile [26]. Each tablet contains dextrose, which is relevant for patients monitoring carbohydrate intake, though the quantities per tablet are negligible.

Dosing Protocol and Monitoring

Armour Thyroid is taken once daily on an empty stomach, at least 30 to 60 minutes before breakfast, consistent with levothyroxine dosing guidelines [27]. The starting dose for most adults with primary hypothyroidism is 30 mg (0.5 grain), with titration in 15 to 30 mg increments every 4 to 6 weeks based on serum TSH. Because T3 is directly absorbed, clinicians should also monitor free T3 levels at each titration step, not relying on TSH alone [28].

TSH Targets and T3 Interpretation

The American Thyroid Association recommends a TSH target of 0.5 to 2.5 mIU/L for most adults on thyroid replacement therapy [29]. When using Armour Thyroid, free T3 levels should ideally be measured 4 to 6 hours after the morning dose to capture the post-absorption peak, not the pre-dose trough, providing the most clinically relevant snapshot of T3 exposure [19]. A trough measurement may underestimate actual T3 exposure and lead to unnecessary dose increases.

Drug Interactions

Calcium carbonate, ferrous sulfate, proton pump inhibitors, and bile acid sequestrants all reduce thyroid hormone absorption when taken within 4 hours of Armour Thyroid [30]. Warfarin sensitivity increases with thyroid hormone replacement; the INR should be rechecked within 4 to 6 weeks of any dose change [30]. Amiodarone, which contains approximately 37% iodine by weight, can suppress peripheral T4-to-T3 conversion and may alter Armour Thyroid's pharmacodynamics unpredictably [31].

Guidelines and Current Prescribing Context

The 2014 American Thyroid Association guidelines state that "levothyroxine should remain the standard of care for hypothyroidism," but add that NDT "may be considered for patients who continue to be symptomatic on LT4" [29]. The Endocrine Society's 2012 clinical practice guideline on hypothyroidism similarly recommends levothyroxine as first-line therapy while acknowledging that combination T4 and T3 therapy, whether through NDT or synthetic combination, may benefit select patients with DIO2 polymorphisms [32].

The British Thyroid Association's 2019 guidelines take a slightly more restrictive stance, recommending that NDT be used only within specialist-supervised trials given limited long-term safety data [33]. This reflects ongoing uncertainty about cardiovascular outcomes with chronic T3 exposure, particularly in patients over 65 or with atrial fibrillation risk [33].

Why Some Patients Continue to Prefer NDT

Patient-preference data from Hoang et al. Showed 49% preferring NDT vs. 19% preferring levothyroxine in a blinded crossover design [20]. This preference signal is not trivial in a condition affecting an estimated 5% of the U.S. Population, approximately 16.5 million people based on NHANES prevalence data [34]. The preference may reflect improved energy, mood, and weight perception, consistent with the mild additional weight loss seen in the Hoang trial.

Research into DIO2 polymorphisms offers one mechanistic explanation. The Thr92Ala variant of the DIO2 gene, present in approximately 12 to 16% of the population, impairs intracellular T4-to-T3 conversion in certain tissues [35]. Patients carrying this variant may not achieve the same intracellular T3 concentrations on levothyroxine as those without the variant, making exogenous T3 supplementation, via NDT or synthetic liothyronine, potentially more effective [35]. Genotyping for DIO2 variants is not yet standard of care but is an area of active investigation.